28,386 Shares in Cellebrite DI Ltd. (NASDAQ:CLBT) Purchased by Healthcare of Ontario Pension Plan Trust Fund

Healthcare of Ontario Pension Plan Trust Fund bought a new position in Cellebrite DI Ltd. (NASDAQ:CLBTFree Report) in the 3rd quarter, HoldingsChannel.com reports. The firm bought 28,386 shares of the company’s stock, valued at approximately $478,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in CLBT. California State Teachers Retirement System raised its holdings in shares of Cellebrite DI by 9.1% in the 1st quarter. California State Teachers Retirement System now owns 56,953 shares of the company’s stock worth $631,000 after purchasing an additional 4,734 shares during the period. Tidal Investments LLC bought a new position in Cellebrite DI during the first quarter worth about $654,000. Harbor Capital Advisors Inc. increased its stake in shares of Cellebrite DI by 311.5% in the second quarter. Harbor Capital Advisors Inc. now owns 48,624 shares of the company’s stock worth $581,000 after purchasing an additional 36,808 shares in the last quarter. Juncture Wealth Strategies LLC bought a new stake in shares of Cellebrite DI in the second quarter valued at approximately $500,000. Finally, Tower View Wealth Management LLC lifted its stake in shares of Cellebrite DI by 6.2% during the 2nd quarter. Tower View Wealth Management LLC now owns 129,147 shares of the company’s stock valued at $1,543,000 after buying an additional 7,542 shares in the last quarter. Hedge funds and other institutional investors own 45.88% of the company’s stock.

Cellebrite DI Trading Up 0.9 %

Shares of CLBT opened at $20.36 on Tuesday. The stock has a 50-day moving average price of $18.28 and a 200-day moving average price of $15.25. The company has a market cap of $4.19 billion, a PE ratio of -13.14, a price-to-earnings-growth ratio of 2.75 and a beta of 1.50. Cellebrite DI Ltd. has a 12-month low of $7.91 and a 12-month high of $21.00.

Cellebrite DI (NASDAQ:CLBTGet Free Report) last released its quarterly earnings results on Wednesday, November 6th. The company reported $0.14 EPS for the quarter, topping analysts’ consensus estimates of $0.09 by $0.05. The business had revenue of $106.90 million during the quarter, compared to analysts’ expectations of $102.06 million. Cellebrite DI had a negative net margin of 82.28% and a positive return on equity of 122.59%. The business’s quarterly revenue was up 27.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.09 EPS. As a group, analysts predict that Cellebrite DI Ltd. will post 0.32 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts recently weighed in on the stock. Lake Street Capital lifted their price objective on shares of Cellebrite DI from $13.50 to $17.00 and gave the company a “buy” rating in a research note on Friday, August 16th. Bank of America boosted their price objective on Cellebrite DI from $13.00 to $17.00 and gave the company a “buy” rating in a research note on Friday, August 16th. JPMorgan Chase & Co. raised their target price on Cellebrite DI from $21.00 to $22.00 and gave the stock an “overweight” rating in a research note on Thursday, November 7th. Craig Hallum upped their price target on Cellebrite DI from $23.00 to $24.00 and gave the company a “buy” rating in a research report on Thursday, November 7th. Finally, Needham & Company LLC raised their price objective on shares of Cellebrite DI from $17.00 to $21.00 and gave the company a “buy” rating in a research report on Thursday, November 7th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $20.29.

Read Our Latest Analysis on CLBT

Cellebrite DI Company Profile

(Free Report)

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.

Recommended Stories

Want to see what other hedge funds are holding CLBT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cellebrite DI Ltd. (NASDAQ:CLBTFree Report).

Institutional Ownership by Quarter for Cellebrite DI (NASDAQ:CLBT)

Receive News & Ratings for Cellebrite DI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellebrite DI and related companies with MarketBeat.com's FREE daily email newsletter.